How Elbow Grease and Inspiration Forged a Winning Career
He was once laughed at for pouring his talent into the “reviled” field of oncology, but Larry Norton, MD, said he was driven by his passion to learn about cancer.
Immunotherapy Combination Explored in Unresectable HCC
Investigators are looking into a combination of immunotherapy agents for patients with unresectable hepatocellular carcinoma, for whom there are limited treatment options in the first line.
CTCs Demonstrate Predictive Power in Prostate Cancer
Investigators looking for a superior means of testing for response to therapy in metastatic castration-resistant prostate cancer said they found the solution in a study of circulating tumor cells.
Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma
The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs.
NGS Testing Hits Clinical Practice
The use of next-generation sequencing to diagnose cancers and guide therapy decisions is expanding as more therapies are linked to genomic abnormalities.
Immunotherapy Poised to Move Forward Into Stage III NSCLC
A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.
MSK Pioneers Interventional Pulmonology Techniques in Lung Cancer Field
Advanced interventional pulmonology techniques are revolutionizing the diagnosis and treatment of lung cancer.
Decision Support Is Lacking in Flood of New Data
Decision support is only lightly touched upon in the academic oncology papers that are published almost daily suggesting a potential change in paradigms for management in a particular clinical setting.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.